ClinicalTrials.gov
public full text
Public Domain
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Senicapoc and Perampanel for Newly Diagnosed Glioblastoma#891053
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms#1096360
- Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission#980579
- GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma#813071
- Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors#67882
Record · ID 1100510
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive